Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now
AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impact
Amsterdam, the Netherlands –
Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology,
has released its 10th annual Future Health Index (FHI) report
, highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. However, gaps in trust threaten to stall progress at a time when innovation is most needed.
'The need to transform healthcare delivery has never been more urgent,' said
Carla Goulart Peron
, M.D., Chief Medical Officer at Philips. 'In more than half of the 16 countries surveyed, patients are waiting nearly two months or more for specialist appointments, with waits in Canada and Spain extending to four months or longer. As healthcare systems face mounting pressures, AI is rapidly emerging as a powerful ally, offering unprecedented opportunities to transform care and overcome today's toughest challenges.'
Long waits, worsening outcomes
The FHI 2025 report reveals 33% of patients have experienced worsening health due to delays in seeing a doctor, and more than 1 in 4 end up in the hospital due to long wait times. 'Cardiac patients face especially dangerous delays, with 31% being hospitalized before even seeing a specialist. Without urgent action, a
projected shortfall of 11 million health workers by 2030
could leave millions without timely care,' Dr. Peron added.
Clinician burnout and data burdens call for digital relief
More than 75% of healthcare professionals report losing clinical time due to incomplete or inaccessible patient data, with one-third losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. 'These inefficiencies amplify stress on already understaffed teams and contribute to burnout,' said Gretchen Brown, RN, VP and Chief Nursing Information Officer at Stanford Health Care. 'Recognizing this, as clinicians, we see AI as a solution and understand that delayed adoption can also carry major risks.'
Of the nearly 2,000 healthcare professionals surveyed, if AI is not implemented:
Trust gaps remain the biggest barrier to widespread AI adoption
While clinicians are generally optimistic, the FHI 2025 report highlights a significant trust gap with patients – 34% more clinicians see AI's benefits than patients do, with optimism especially lower among patients aged 45 and older. Even among clinicians, skepticism remains: 69% are involved in AI and digital technology development, but only 38% believe these tools meet real-world needs. Concerns around accountability persist, with over 75% unclear about liability for AI-driven errors. Data bias is another major worry, as it risks deepening healthcare disparities if left unaddressed. 'To build trust with clinicians, we need education, transparency in decision-making, rigorous validation of models, and the involvement of healthcare professionals in every step of the process,' Brown added.
The path forward: human-centric AI integration
Patients want AI to work safely and effectively, reducing errors, improving outcomes, and enabling more personalized, compassionate care. Clinicians say trust hinges on clear legal and ethical standards, strong scientific validation, and continuous oversight. As AI reshapes healthcare, building trust is essential to delivering life-saving innovation faster and at scale.
'To realize the full potential of AI, regulatory frameworks must evolve to balance rapid innovation with robust safeguards to ensure patient safety and foster trust among clinicians,' said
Shez Partovi
, Chief Innovation Officer at Philips. 'By 2030, AI could transform healthcare by automating administrative tasks, potentially doubling patient capacity as AI agents assist, learn, and adapt alongside clinicians. To that end, we must design AI with people at the center—built in collaboration with clinicians, focused on safety, fairness, and representation—to earn trust and deliver real impact in patient care.'
About the Future Health Index 2025
The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit
www.philips.com/futurehealthindex-2025
.
For further information, please contact:
Kathy O'Reilly
Philips Global External Relations
Tel.: +1 978-807-1449
E-mail:
kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at
www.philips.com/newscenter
.
Attachments
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Labcorp Holdings Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Labcorp Holdings (NYSE:LH) Second Quarter 2025 Results Key Financial Results Revenue: US$3.53b (up 9.5% from 2Q 2024). Net income: US$237.9m (up 16% from 2Q 2024). Profit margin: 6.7% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$2.85 (up from US$2.44 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Labcorp Holdings Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are up 8.7% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Labcorp Holdings. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Forbes
3 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
Yahoo
6 hours ago
- Yahoo
Molina Healthcare (MOH) Dragged 16.8% by Lower Outlook
We recently published . Molina Healthcare, Inc. (NYSE:MOH) is one of the worst-performing stocks on Thursday. Molina Healthcare ended two straight days of rally on Thursday, dropping 16.84 percent to close at $158.22 apiece as investor sentiment was dampened by its lower earnings outlook for the year. In a statement, Molina Healthcare, Inc. (NYSE:MOH) lowered its adjusted EPS outlook by 22 percent to only $19 from the $24.5 guidance previously. Total revenues were also expected to settle at $44 billion, or 8.37 percent higher than the $40.65 billion in 2024. In the second quarter of the year, Molina Healthcare, Inc. (NYSE:MOH) saw net income decline by 15 percent to $255 million from $301 million in the same period last year, pulling net profit for the first half lower by 8 percent to $553 million from $602 million year-on-year. 15 States with the Best Healthcare in the US Total revenues during the quarter increased by 15 percent to $11.4 billion from $9.88 billion, while revenues for the first semester grew by 13.6 percent to $22.57 billion from $19.8 billion year-on-year. While we acknowledge the potential of MOH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
